🇺🇸 FDA

P1 · Therapeutic area intelligence

Obesity & metabolic patent intelligence

GLP-1, GIP/GLP-1, diabetes, and metabolic disease patents — critical for obesity market IP tracking.

Patents
276

Quick answer

276 US pharmaceutical patents in our index match Obesity & metabolic title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 9511103

    AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9511038

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    The Regents of the University of California · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9463254

    Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI

    The Board of Regents of the University of Texas System · Granted Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9433624

    Methods and compositions for the treatment of metabolic disorders

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9393271

    GHRH agonists for islet cell transplantation and function and the treatment of diabetes

    THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Jul 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9226910

    Treatment for obesity

    Jazz Pharmaceuticals International III Limited · Granted Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9221800

    Isoxazole treatments for diabetes

    The Board of Regents of the University of Texas System · Granted Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9220735

    Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders

    AKER BIOMARINE ANTARCTIC AS · Granted Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9198901

    Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof

    VTV THERAPEUTICS LLC · Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9186421

    Establishment of rhesus monkey model of autoimmunity type 1 diabetes

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9163258

    Method for the treatment of obesity

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9149448

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    The Regents of the University of California · Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9138479

    Formulations for the treatment of diabetes

    XERIS PHARMACEUTICALS, INC. · Granted Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9133127

    Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

    Jenrin Discovery, LLC · Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9120813

    Oxadiazoanthracene compounds for the treatment of diabetes

    VTV THERAPEUTICS LLC · Granted Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9095550

    Methods for treating diabetic wounds

    CALREGEN INC. · Granted Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9089531

    GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

    The Regents of the University of California · Granted Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9067962

    Methods of treating diabetes

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9056847

    Activity based probes (ABPs) interacting with glycosidases

    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM · Granted Tue Jun 16 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9029413

    Treatment of viral infections by modulation of host cell metabolic pathways

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9006201

    Prophylactic or therapeutic agent for diabetes

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8987198

    Compositions and methods for treating obesity and diabetes

    United States Department of Agriculture · Granted Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8961982

    Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer

    The Regents of the University of California · Granted Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8957070

    Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8889133

    Methods of treating diabetes with Dll4 antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8865914

    Fluorescent probes for detection of copper

    The Regents of the University of California · Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8853160

    GLP-1, exendin-4, peptide analogs and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8853252

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8853215

    Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8828971

    Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders

    GALECTIN THERAPEUTICS, INC. · Granted Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8741589

    Monitoring two dimensions of diabetes pathogenesis

    The Regents of the University of California · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8729115

    Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases

    CARDIOLYNX AG · Granted Tue May 20 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8722716

    Isoxazole treatments for diabetes

    The Board of Regents of the University of Texas System · Granted Tue May 13 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8697138

    Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders

    Aker Biomarine AS · Granted Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8697628

    Methods of using AMPD2 inhibitors for the treatment of fatty liver, obesity and diabetes

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8680131

    Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

    Jenrin Discovery, LLC · Granted Tue Mar 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8653027

    Method of treatment of type-1 diabetes with humanin analogues

    The Regents of the University of California · Granted Tue Feb 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8648072

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Feb 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8580919

    Polymer conjugates of GLP-1

    Nektar Therapeutics · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8580768

    Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8563614

    Use of treprostinil to treat neuropathic diabetic foot ulcers

    United Therapeutics Corporation · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8541456

    Roflumilast for the treatment of diabetes mellitus type 2

    TAKEDA GMBH · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8541475

    MAO-B inhibitors useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8492405

    Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8426597

    Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

    CARDIOLYNX AG · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8420612

    Diabetes treatment methods and drug targets therefor

    The Regents of the University of California · Granted Tue Apr 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8404869

    Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome

    MAZENCE INC. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8383580

    Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Obesity & metabolic patents are indexed?

276 patents match our Obesity & metabolic classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.